These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 39301017)

  • 1. Humoral and cellular immune response from first to fourth SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients-a longitudinal cohort study.
    Novak F; Nilsson AC; Christensen EB; Stougaard CL; Barnkob MB; Holm DK; Witt AH; Byg KE; Johansen IS; Nielsen C; Sejbaek T
    Front Immunol; 2024; 15():1432348. PubMed ID: 39301017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
    Bajwa HM; Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Witt AH; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
    Mult Scler Relat Disord; 2022 Apr; 60():103729. PubMed ID: 35334278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
    Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
    Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
    Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
    Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses.
    Novak F; Bajwa HM; Coia JE; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Hvidt MVM; Byg KE; Johansen IS; Mittl K; Rowles W; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
    J Neurol Neurosurg Psychiatry; 2023 Nov; 94(11):934-937. PubMed ID: 37185261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
    Sabatino JJ; Mittl K; Rowles W; Zamecnik CR; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Alexander J; Mcpolin K; Chen P; Deshpande C; Wyse K; Maiese EM; Wilson MR; Zamvil SS; Bove R
    Mult Scler Relat Disord; 2023 Feb; 70():104484. PubMed ID: 36608538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
    Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
    JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.
    Liu WD; Lin MS; Sun HY; Shih MC; Chuang YC; Huang YS; Lin KY; Li GC; Wu PY; Chen LY; Liu WC; Su YC; He PC; Chen YT; Lin CY; Cheng YC; Yao Y; Yeh YC; Liu CC; Pan MY; Luo YZ; Chang HY; Wang JT; Sheng WH; Hsieh SM; Chang SY; Hung CC
    J Microbiol Immunol Infect; 2024 Aug; 57(4):554-563. PubMed ID: 38429206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hybrid immunity by two COVID-19 mRNA vaccinations and one breakthrough infection provides a robust and balanced cellular immune response as basic immunity against severe acute respiratory syndrome coronavirus 2.
    Almanzar G; Koosha K; Vogt T; Stein A; Ziegler L; Asam C; Weps M; Schwägerl V; Richter L; Hepp N; Fuchs A; Wagenhäuser I; Reusch J; Krone M; Geldmacher C; Protzer U; Steininger P; Überla K; Wagner R; Liese J; Prelog M
    J Med Virol; 2024 Jun; 96(6):e29739. PubMed ID: 38899449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.
    Verstegen NJM; Hagen RR; Kreher C; Kuijper LH; Dijssel JVD; Ashhurst T; Kummer LYL; Palomares Cabeza V; Steenhuis M; Duurland MC; Jongh R; Schoot CEV; Konijn VAL; Mul E; Kedzierska K; van Dam KPJ; Stalman EW; Boekel L; Wolbink G; Tas SW; Killestein J; Rispens T; Wieske L; Kuijpers TW; Eftimov F; van Kempen ZLE; van Ham SM; Ten Brinke A; van de Sandt CE;
    J Neurol Neurosurg Psychiatry; 2024 Aug; 95(9):855-864. PubMed ID: 38548324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Wagenhäuser I; Almanzar G; Förg FB; Stein A; Eiter I; Reusch J; Mees J; Herzog A; Vogel U; Frey A; Lâm TT; Schubert-Unkmeir A; Dölken L; Kurzai O; Frantz S; Gabel A; Petri N; Prelog M; Krone M
    Vaccine; 2024 Aug; 42(21):126132. PubMed ID: 39034219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
    Novak F; Nilsson AC; Nielsen C; Holm DK; Østergaard K; Bystrup A; Byg KE; Johansen IS; Mittl K; Rowles W; Mcpolin K; Spencer C; Sagan S; Gerungan C; Wilson MR; Zamvil SS; Bove R; Sabatino JJ; Sejbaek T
    Mult Scler Relat Disord; 2021 Nov; 56():103251. PubMed ID: 34571415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
    Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
    Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the induction of humoral and cellular immunity by third vaccination for SARS-CoV-2.
    Murayama G; Kusaoi M; Horiuchi Y; Tabe Y; Naito T; Ito S; Yamaji K; Tamura N
    J Infect Chemother; 2024 Oct; 30(10):1021-1027. PubMed ID: 38570139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Apostolidis SA; Kakara M; Painter MM; Goel RR; Mathew D; Lenzi K; Rezk A; Patterson KR; Espinoza DA; Kadri JC; Markowitz DM; E Markowitz C; Mexhitaj I; Jacobs D; Babb A; Betts MR; Prak ETL; Weiskopf D; Grifoni A; Lundgreen KA; Gouma S; Sette A; Bates P; Hensley SE; Greenplate AR; Wherry EJ; Li R; Bar-Or A
    Nat Med; 2021 Nov; 27(11):1990-2001. PubMed ID: 34522051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
    Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
    Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunity following SARS-CoV-2 vaccination in autoimmune neurological disorders treated with rituximab or ocrelizumab.
    Nytrova P; Stastna D; Tesar A; Menkyova I; Posova H; Koprivova H; Mikulova V; Hrdy J; Smela G; Horakova D; Rysankova I; Doleckova K; Tyblova M
    Front Immunol; 2023; 14():1149629. PubMed ID: 37398654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.